fig2
![Hepatocellular carcinoma recurrence in HCV patients treated with direct-acting antivirals after curative treatment](https://image.oaes.cc/51cf190d-d312-48af-80da-ca0b6bab0d9f/3075.fig.2.jpg)
Figure 2. The overall survival in patients treated with DAAs after curative treatment for HCC. The survival rates at 1, 2 and 3 years were 99%, 98% and 95%, respectively. HCC: hepatocellular carcinoma; DAA: direct-acting antiviral
Figure 2. The overall survival in patients treated with DAAs after curative treatment for HCC. The survival rates at 1, 2 and 3 years were 99%, 98% and 95%, respectively. HCC: hepatocellular carcinoma; DAA: direct-acting antiviral
All published articles are preserved here permanently:
https://www.portico.org/publishers/oae/